Wall Street Titan
Contributor since: 2011
Avita Medical: A Better Mousetrap With FDA Approval To Treat Patient Burns
Keeping Focused Amidst The Biotech Bear
Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent
An Interview With Athersys' CEO
Mesoblast Signs Deal In China For Stem Cell Heart Therapies
Athersys/Healios Warrant Structure Bullish For Athersys Shares
Athersys Gets $56 Million From Healios In Stem Cell Deal
A Deep Drill Down To Walmart's Problem In E-Commerce
Athersys Poised For Lucrative Stem Cell Stroke Partnership This Year
BrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate
President Obama Signs 21st Century Cures Act - Implications For The Stem Cell Sector
Marketplace Roundtable: The State Of Biotech
All Systems Go On Athersys Pivotal Stem Cell Stroke Trial In Japan - Exploring The Scientific Evidence
Brainstorm Cell Therapeutics: Caution Ahead Of ALS Phase II Data
Stem Cell Company Athersys Firing On All Cylinders In 2016
Cytori Cell Therapy Shows Promising Results In The Erectile Dysfunction Stem Cell Study
Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again
Top Stock Idea For 2016? - Athersys, A Beaten Down Stem Cell Stock With Great Upside
Ocata Management Pulls Out All Stops To Push Astellas Merger Forward
Stem Cell Company Cesca Therapeutics' Bad Idea
Astellas To Acquire Stem Cell Company Ocata Therapeutics At 90% Premium - What Does It Mean For The Stem Cell Sector?
WST Exclusive: Why Chugai And Athersys Parted Ways On Japan Stroke Stem Cell Program
The Forgotten Stem Cell Sector Is Making Substantive Progress
Correcting The Facts On Cytori Therapeutics
Date And Time Is Set For Athersys Phase II Stroke Presentation
A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results
Memo To Prospect Capital Management: Aggressively Buy Back Discounted Shares
Athersys Could Benefit Immensely From Japan Reimbursement On Stroke
GoPro Weak First Quarter - What Investors Are Missing
Athersys: Down But Not Out - An Interview With CEO Van Bokkelen
Cytori Therapeutics Announces Date For Crucial BARDA Meeting
Fuel Cell Energy Reality Check: A Valuation Comparison To First Solar